Phase III news from FierceBiotech
NewsJPMorgan steps in for Myriad Genetics review
Fresh on the heels of its Phase III disaster with the Alzheimer's drug Flurizan, Myriad Read more...
Vertex readies new Phase 3 trial of telaprevir
Vertex and partner Johnson & Johnson have struck agreements with regulators on both sides of the Atlantic for a new Phase III trial of the closely-watched telaprevir for hepatitis C. This new Read more...
Altus shares nosedive despite Phase III success
Hitting a primary endpoint in a late-stage trial is not always a recipe for success, it seems. Shares of Altus Pharmaceuticals nosedived this morning after the company issued a release saying that Read more...
J&J psoriasis drug may carry cancer risk
Outside experts are preparing to review ustekinumab, Centocor's injectable treatment of severe psoriasis. Two Phase III studies demonstrated Read more...
Jazz Pharma axes staffers after delaying two trials
Jazz Pharmaceuticals says it needs to extend the development time line for two key drug programs, a move that triggered a decision to lay off 33 workers, or eight percent of its workforce. In a Read more...
Novo Nordisk discontinues Phase III on disappointing results
Concluding that a late-stage trial of its experimental therapy to prevent bleeding in trauma patients was headed to a likely failure, Novo Nordisk discontinued the study of Read more...
BioSante Pharma exploring its strategic alternatives
BioSante Pharmaceuticals has brought in Deutsche Bank to advise the company on its "strategic alternatives." The developer has advanced LibiGel, a topical therapy for female sexual dysfunction, into Read more...
GSK collaborates on immune disease research
GlaxoSmithKline has inked a five year, $25 million collaboration deal with the Disease Institute of Boston to conduct on immunoinflammation research. GSK and IDI researchers will develop joint grant Read more...
Indevus shares plunge on approval delay
Indevus is facing a major setback in its efforts to gain approval for Nebido. The drug treats male hypogonadism, a condition in which the testicles fail to produce enough testosterone. Indevus said Read more...
| Press ReleasesPRESS RELEASE: MediQuest Announces Positive Results from Phase III Study MediQuest Announces Positive Results from Phase III Study Trial Holds Promise for Millions Suffering from Raynaud's Disease BOTHELL, WA - Nov. 8, 2007 - MediQuest Therapeutics today announced that Read more... PRESS RELEASE: Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis BOSTON, Nov. 7 -- Patients with active psoriatic Read more... PRESS RELEASE: Novacea Halts Late-Stage Trial of Prostate Cancer Drug Asentar Novacea Halts Late-Stage Trial of Prostate Cancer Drug Asentar SOUTH SAN FRANCISCO, CA - Nov 5, 2007 -- Novacea announced today that the company has ended its Phase 3 ASCENT-2 clinical trial of Read more... PRESS RELEASE: GPC Biotech and Pharmion Announce Results of Overall Survival Analysis from the Satraplatin Pivotal Phase 3 Trial GPC Biotech and Pharmion Announce Results of Overall Survival Analysis from the Satraplatin Pivotal Phase 3 Trial • Overall survival results do not achieve statistical significance • GPC Biotech Read more... PRESS RELEASE: Sirion Therapeutics Announces Positive Phase III Results for Difluprednate Sirion Therapeutics Announces Positive Phase III Results for Difluprednate TAMPA, Fla., Oct. 25 -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced Read more... |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets